Yakup Ergün· @dr_yakupergun · X·· 1 day agoScore70
Body
#ESMO26 | FOURLIGHT-1
In HR+/HER2− mBC after CDK4/6i, the selective CDK4 inhibitor atirmociclib + fulvestrant improved PFS.
PFS: 9.4 vs 6.6 mo (HR 0.60)
12-month PFS: 44.8% vs 22.5%
Selective CDK4 inhibition after CDK4/6 inhibition! The sustained separation of the PFS curves is noteworthy.
22 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
1842Omatched by Proffered paper 2: Breast cancer, early and advanced stage
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.orgSource: Yakup Ergün · x.com